NASDAQ:NTLAIntellia Therapeutics Stock Price, Forecast & News

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NTLA stock has increased by 56.1% and is now trading at $19.86. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intellia Therapeutics.

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Intellia Therapeutics.

Intellia Therapeutics Inc (NASDAQ:NTLA) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.24. The company earned $12.92 million during the quarter, compared to analyst estimates of $21.98 million. Intellia Therapeutics had a negative net margin of 239.98% and a negative return on equity of 40.89%. The business's revenue was up 23.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.49) earnings per share. View Intellia Therapeutics' earnings history.

7 brokers have issued 1 year price objectives for Intellia Therapeutics' stock. Their forecasts range from $16.00 to $57.50. On average, they expect Intellia Therapeutics' share price to reach $26.42 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price. View analysts' price targets for Intellia Therapeutics.

News articles about NTLA stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Intellia Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutIntellia Therapeutics.

Some companies that are related to Intellia Therapeutics include Neogen (NEOG), Myriad Genetics (MYGN), Heska (HSKA), Meridian Bioscience (VIVO), Quotient (QTNT), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Vermillion (VRML), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), ImmuCell (ICCC), GeneNews (GNWSF) and Achieve Life Sciences (ACHV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Square (SQ), InVitae (NVTA), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and Sangamo Therapeutics (SGMO).

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Nikko Asset Management Americas Inc. (13.81%), Sumitomo Mitsui Trust Holdings Inc. (14.51%), Nikko Asset Management Americas Inc. (13.81%), BlackRock Inc. (7.38%), State Street Corp (3.36%) and Morgan Stanley (1.26%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier and Jean Francois Formela. View institutional ownership trends for Intellia Therapeutics.

NTLA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Nuveen Asset Management LLC, Two Sigma Investments LP, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Bank of New York Mellon Corp, and Deutsche Bank AG. View insider buying and selling activity for Intellia Therapeutics.

NTLA stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, BlackRock Inc., JPMorgan Chase & Co., Geode Capital Management LLC, Aigen Investment Management LP, State Street Corp, Los Angeles Capital Management & Equity Research Inc., and Two Sigma Advisers LP. View insider buying and selling activity for Intellia Therapeutics.

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NTLA stock can currently be purchased for approximately $19.86.

Intellia Therapeutics has a market capitalization of $1.02 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.

The official website for Intellia Therapeutics is www.intelliatx.com.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]